Loading…
Recursion Pharmaceuticals, Inc. is projected to rise to $3.91 by 2027, a +23% move from its current price of $3.17. RXRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.08 | $3.17 | $3.27 | +0.08% |
| May 30 | $3.04 | $3.17 | $3.31 | +0.16% |
| May 31 | $3.02 | $3.18 | $3.35 | +0.24% |
| Jun 1 | $3.00 | $3.18 | $3.38 | +0.31% |
| Jun 2 | $2.98 | $3.18 | $3.40 | +0.39% |
| Jun 3 | $2.96 | $3.18 | $3.43 | +0.47% |
| Jun 4 | $2.95 | $3.19 | $3.45 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.95 | $3.19 | $3.45 | +0.55% |
| Week 2 | $2.87 | $3.20 | $3.58 | +1.10% |
| Week 3 | $2.81 | $3.22 | $3.69 | +1.66% |
| Week 4 | $2.77 | $3.24 | $3.79 | +2.22% |
| Week 5 | $2.73 | $3.26 | $3.89 | +2.78% |
| Week 6 | $2.70 | $3.28 | $3.97 | +3.34% |
| Week 7 | $2.67 | $3.29 | $4.06 | +3.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare stock trading with a current price of $3.01.
It has a market capitalization of $1.6B and is ranked 2177. The multi-year forecast suggests a bullish long-term trajectory, with average prices rising across selected years and notable upside potential by 2040 and 2050. For example, the 2040 average is projected at $6.73 with a max of $11.47 and a 123.4% implied ROI, while 2050 shows an average of $11.44 with a max of $21.36 and a 280% implied ROI.
Across the forecast years, the average price moves from $3.01 in 2026 to higher levels in subsequent years, including $3.69 (2027), $3.89 (2028), $3.69 (2029), $3.71 (2030), $3.87 (2031), $4.00 (2032), $4.82 (2033), $5.12 (2034), and $5.14 (2035); with longer-horizon forecasts of $6.73 (2040) and $11.44 (2050). The corresponding ROIs by year include 0 (2026), 22.7 (2027), 29.3 (2028), 22.7 (2029), 23.4 (2030), 28.5 (2031), 33 (2032), 60.3 (2033), 70 (2034), 70.8 (2035), 123.4 (2040), and 280 (2050). Sentiment switches to BULLISH from 2027 onward, signaling a growing optimism in the long run.
A major floor 26.3% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 19.2% above — a clean break opens room to run.
A major ceiling 56.5% above — clearing it would confirm fresh momentum.
Key RXRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RXRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.04 | Buy | $3.05 | Buy |
| MA 10 | $3.00 | Buy | $3.06 | Buy |
| MA 20 | $3.17 | Sell | $3.14 | Buy |
| MA 50 | $3.28 | Sell | $3.32 | Sell |
| MA 100 | $3.65 | Sell | $3.62 | Sell |
| MA 200 | $4.29 | Sell | $4.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.20 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -0.94 | Neutral |
| Williams %R (14) | -31.91 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.52 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 68.09 | Neutral |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 56.11 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 3.08 | Buy |
| ADX (14) | 15.69 | Neutral |
| ATR (14) | 0.10 | Info |
Current technical setup shows a BEARISH sentiment, with RSI(14) at 40. The 50-day simple moving average sits at $3.29, while the 200-day simple moving average stands at $4.32. A near-term support level is identified at $2.85 and a near-term resistance at $3.78.
The 30-day price range spans from $2.50 to $3.62, highlighting limited upside in the very near term. The stock also exhibits higher annualized volatility at 50%, underscoring elevated risk in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.84 | $3.17 | $4.52 | 0% | Neutral | |
| $3.08 | $3.91 | $5.29 | +23% | Bullish | |
| $3.19 | $4.18 | $5.87 | +32% | Bullish | |
| $2.92 | $3.92 | $5.68 | +24% | Bullish | |
| $2.88 | $3.96 | $5.88 | +25% | Bullish | |
| $2.97 | $4.16 | $6.32 | +31% | Bullish | |
| $3.01 | $4.30 | $6.67 | +36% | Bullish | |
| $3.63 | $5.28 | $8.34 | +67% | Bullish | |
| $3.79 | $5.61 | $9.00 | +77% | Bullish | |
| $3.70 | $5.57 | $9.08 | +76% | Bullish | |
| $4.61 | $7.47 | $13.00 | +136% | Bullish | |
| $6.78 | $12.55 | $23.99 | +296% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.84 | $3.17 | $3.75 | +0.00% |
| June 2026 | $2.85 | $3.36 | $4.05 | +5.97% |
| July 2026 | $2.87 | $3.40 | $4.17 | +1.35% |
| August 2026 | $2.82 | $3.37 | $4.17 | -1.06% |
| September 2026 | $2.88 | $3.47 | $4.33 | +2.89% |
| October 2026 | $2.95 | $3.57 | $4.50 | +2.99% |
| November 2026 | $2.90 | $3.52 | $4.47 | -1.28% |
| December 2026 | $2.90 | $3.54 | $4.52 | +0.47% |
Click any year to see its month-by-month RXRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RXRX to range from $2.84 to $4.52 through 2026. The $3.17 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RXRX price prediction for 2027 points to an average of $3.91 (low $3.08, high $5.29) — a potential gain of +23% on today's $3.17. Momentum favours further upside here.
In 2028, RXRX is projected to trade between $3.19 and $5.87, averaging $4.18 — a potential gain of +32% from today's $3.17. That is up +7% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Recursion Pharmaceuticals, Inc.'s 2029 outlook centres on $3.92, within a $2.92 to $5.68 range. That is -6% versus the projected 2028 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2030, RXRX could reach as high as $5.88, with a base case around $3.96 and support toward $2.88 — roughly +25% from $3.17. Buyers look set to stay in control over this stretch.
Expect RXRX to range from $2.97 to $6.32 through 2031. The $4.16 average target implies a +31% move from current prices. That is up +5% on the projected 2030 average. Momentum favours further upside here.
The RXRX price prediction for 2032 points to an average of $4.30 (low $3.01, high $6.67) — a potential gain of +36% on today's $3.17. Buyers look set to stay in control over this stretch.
In 2033, RXRX is projected to trade between $3.63 and $8.34, averaging $5.28 — a potential gain of +67% from today's $3.17. That is up +23% on the projected 2032 average. Momentum favours further upside here.
Recursion Pharmaceuticals, Inc.'s 2034 outlook centres on $5.61, within a $3.79 to $9.00 range. That is up +6% on the projected 2033 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RXRX could reach as high as $9.08, with a base case around $5.57 and support toward $3.70 — roughly +76% from $3.17. Momentum favours further upside here.
Expect RXRX to range from $4.61 to $13.00 through 2040. The $7.47 average target implies a +136% move from current prices. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RXRX price prediction for 2050 points to an average of $12.55 (low $6.78, high $23.99) — a potential gain of +296% on today's $3.17. Momentum favours further upside here.
Investing $1,000 in RXRX today (≈ 315.457413 RXRX) could be worth
$3,957.78
+$2,957.78 (+296%) by 2050 · US Dollar
Based on the average projected RXRX price of $12.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RXRXwould be worth at today's price.
$1,000 invested in RXRX on May 27, 2025 (≈ 227.79044 RXRX) would be worth
$722.1
-$277.9 (-27.8%) today · 0.72× · US Dollar
Based on a RXRX entry price of $4.39 vs. today's $3.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.96 | $1,070.95 | +7.1% |
| 1 month ago | $3.48 | $910.92 | -8.9% |
| 3 months ago | $3.77 | $840.85 | -15.9% |
| 6 months ago | $4.63 | $684.67 | -31.5% |
| 1 year ago | $4.39 | $722.1 | -27.8% |
| All time (5.0y) ago | $28.48 | $111.31 | -88.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RXRX forecast.
Our base-case forecast reaches $6.30 around 2040.
Implied market cap at $6.30: $3.31B
The multi-year forecast paints a bullish long-term picture. For 2027 the average price is $3.69 with an implied RO I of 22.7 and bullish sentiment, followed by a 2028 average of $3.89 (ROI 29.3) and a 2029 average of $3.69 (ROI 22.7), culminating in 2030 with an average of $3.71 (ROI 23.4).
Stepping into 2031 the average rises to $3.87 (ROI 28.5), 2032 to $4.00 (ROI 33), and 2033 to $4.82 (ROI 60.3), with further gains through 2034 at $5.12 (ROI 70) and 2035 at $5.14 (ROI 70.8). The forecast then accelerates, with 2040 projecting an average of $6.73 (ROI 123.4) and a max of $11.47, and 2050 projecting an average of $11.44 (ROI 280) with a max of $21.36.
These figures are estimates tied to the stated year-by-year forecasts and are not guarantees. They reflect the modeled trajectory under the given assumptions and carry inherent uncertainty and risks, including market dynamics and pipeline progress.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.71 with a min of $2.73 and a max of $5.44, representing an implied ROI of 23.4 and a bullish sentiment.
The longer-term forecast shows a bullish trajectory with rising averages, including a 2040 average of $6.73 and a 2050 average of $11.44, with corresponding ROIs of 123.4 and 280. These are estimates, not guarantees.
The current price is $3.01 and the market capitalization is $1.6B.
The 2040 forecast shows a min of $4.25, an average of $6.73, and a max of $11.47, with an ROI of 123.4.
The near-term picture shows a BEARISH sentiment with RSI(14) at 40. The 50-day SMA is $3.29, the 200-day SMA is $4.32, a support at $2.85, a resistance at $3.78, and a 30-day price range of $2.50 to $3.62.
Recursion Pharmaceuticals, Inc. Community Discussion
0Share your Recursion Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.